These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11127101)

  • 21. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
    Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
    Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of rapid prescreening and 10% rescreening in liquid-based Papanicolaou testing.
    Currens HS; Nejkauf K; Wagner L; Raab SS
    Am J Clin Pathol; 2012 Jan; 137(1):150-5. PubMed ID: 22180489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health service utilization among Alzheimer's disease patients: evidence from managed care.
    Frytak JR; Henk HJ; Zhao Y; Bowman L; Flynn JA; Nelson M
    Alzheimers Dement; 2008 Sep; 4(5):361-7. PubMed ID: 18790463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A clinical trial of the AutoPap 300 QC system for quality control of cervicovaginal cytology in the clinical laboratory.
    Colgan TJ; Patten SF; Lee JS
    Acta Cytol; 1995; 39(6):1191-8. PubMed ID: 7483997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis.
    Huse DM; Song X; Ozminkowski RJ; Maguire J; Williams SA; Borok GM; McDonough K
    Clin Ther; 2006 Sep; 28(9):1425-42. PubMed ID: 17062315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening.
    Bidus MA; Maxwell GL; Kulasingam S; Rose GS; Elkas JC; Chernofsky M; Myers ER
    Obstet Gynecol; 2006 May; 107(5):997-1005. PubMed ID: 16648402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patterns of mental health utilization and costs among children in a privately insured population.
    Leslie DL; Rosenheck RA; Horwitz SM
    Health Serv Res; 2001 Apr; 36(1 Pt 1):113-27. PubMed ID: 11324739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Semi-automated cervical smear pre-screening systems: an evaluation of the Cytoscan-110.
    Husain OA; Watts KC; Lorriman F; Butler B; Tucker J; Carothers A; Eason P; Farrow S; Rutovitz D; Stark M
    Anal Cell Pathol; 1993 Jan; 5(1):49-68. PubMed ID: 8424901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New tests for cervical cancer screening.
    Nuovo J; Melnikow J; Howell LP
    Am Fam Physician; 2001 Sep; 64(5):780-6. PubMed ID: 11563569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The 1996 revision of the Dutch cervical cancer screening programme: increased coverage, fewer repeat smears and less opportunistic screening].
    Berkers LM; van Ballegooijen M; van Kemenade FJ; Rebolj M; Essink-Bot ML; Helmerhorst TJ; Habbema JD
    Ned Tijdschr Geneeskd; 2007 Jun; 151(23):1288-94. PubMed ID: 17624160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam.
    Suba EJ; Nguyen CH; Nguyen BD; Raab SS;
    Cancer; 2001 Mar; 91(5):928-39. PubMed ID: 11251944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of a tailored intervention to increase screening in HMO women overdue for Pap test and mammography services.
    Lynch FL; Whitlock EP; Valanis BG; Smith SK
    Prev Med; 2004 Apr; 38(4):403-11. PubMed ID: 15020173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospects for newer technologies in cervical cancer screening programmes.
    Hailey DM; Lea R
    J Qual Clin Pract; 1995 Sep; 15(3):139-45. PubMed ID: 8528539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An economic model for comparing alternative policies for cervical cytologic smear screening.
    Kaminsky FC; Burke RJ; Haberle KR; Mullins DL
    Acta Cytol; 1995; 39(2):232-8. PubMed ID: 7887070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of women with abnormal cervical cytology: treatment patterns and associated costs in England and Wales.
    Martin-Hirsch P; Rash B; Martin A; Standaert B
    BJOG; 2007 Apr; 114(4):408-15. PubMed ID: 17378815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Automated rescreening in cervical cytology. Mathematical models for evaluating overall process sensitivity, specificity and cost.
    Kaminsky FC; Benneyan JC; Mullins DL
    Acta Cytol; 1997; 41(1):209-23. PubMed ID: 9022745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The ultimate goal? It depends.
    Brown E
    Physician Exec; 1996 Oct; 22(10):50-2. PubMed ID: 10162496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaginal pH as an OTC screening tool for vaginitis.
    Wysocki S
    Adv Nurse Pract; 2009 Oct; 17(10):29-33, 44. PubMed ID: 20000160
    [No Abstract]   [Full Text] [Related]  

  • 40. Increased cervical cytologic smear access through increased capacity.
    Shaver JL
    J Reprod Med; 1998 Nov; 43(11):1005-6. PubMed ID: 9839272
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.